NZ623140B2 - Methods and systems for identifying and treating anti-progestin sensitive tumors - Google Patents
Methods and systems for identifying and treating anti-progestin sensitive tumors Download PDFInfo
- Publication number
- NZ623140B2 NZ623140B2 NZ623140A NZ62314012A NZ623140B2 NZ 623140 B2 NZ623140 B2 NZ 623140B2 NZ 623140 A NZ623140 A NZ 623140A NZ 62314012 A NZ62314012 A NZ 62314012A NZ 623140 B2 NZ623140 B2 NZ 623140B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- tumor
- progesterone receptor
- cells
- progesterone
- antibody
- Prior art date
Links
- 239000003418 antiprogestin Substances 0.000 title claims abstract description 102
- 230000000708 anti-progestin Effects 0.000 title claims abstract description 91
- 206010028980 Neoplasm Diseases 0.000 title claims description 138
- 102000003998 progesterone receptors Human genes 0.000 claims abstract description 274
- 108090000468 progesterone receptors Proteins 0.000 claims abstract description 274
- 210000004027 cells Anatomy 0.000 claims abstract description 139
- 210000001519 tissues Anatomy 0.000 claims abstract description 127
- 238000009826 distribution Methods 0.000 claims abstract description 85
- 210000004940 Nucleus Anatomy 0.000 claims abstract description 41
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 claims abstract description 40
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims abstract description 40
- 239000000186 progesterone Substances 0.000 claims abstract description 40
- 229960003387 progesterone Drugs 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 19
- 230000012010 growth Effects 0.000 claims abstract description 18
- 229940000406 drug candidates Drugs 0.000 claims abstract description 17
- 230000000381 tumorigenic Effects 0.000 claims abstract description 10
- 231100000588 tumorigenic Toxicity 0.000 claims abstract description 10
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 108090001123 antibodies Proteins 0.000 claims description 143
- 102000004965 antibodies Human genes 0.000 claims description 143
- 230000027455 binding Effects 0.000 claims description 75
- 102000005962 receptors Human genes 0.000 claims description 29
- 108020003175 receptors Proteins 0.000 claims description 29
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 claims description 27
- 229950011093 Onapristone Drugs 0.000 claims description 27
- 229940079593 drugs Drugs 0.000 claims description 18
- 210000000481 Breast Anatomy 0.000 claims description 15
- 238000001574 biopsy Methods 0.000 claims description 12
- 230000003623 progesteronic Effects 0.000 claims description 11
- 230000002357 endometrial Effects 0.000 claims description 10
- 210000003855 Cell Nucleus Anatomy 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 230000003247 decreasing Effects 0.000 claims description 8
- HKDLNTKNLJPAIY-WKWWZUSTSA-N (8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)C(C)=O)[C@]2(C)C1 HKDLNTKNLJPAIY-WKWWZUSTSA-N 0.000 claims description 7
- 229950003620 Asoprisnil Drugs 0.000 claims description 7
- VKHAHZOOUSRJNA-GCNJZUOMSA-N Mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims description 7
- 230000001747 exhibiting Effects 0.000 claims description 7
- -1 istone Chemical compound 0.000 claims description 7
- 229960003248 mifepristone Drugs 0.000 claims description 7
- 229960000200 ulipristal Drugs 0.000 claims description 7
- IJLXLZGJDSJGIQ-BILPMHSYSA-N (8R,9S,10R,13S,14S,16R,17S)-16-ethyl-17-(2-hydroxyacetyl)-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1C[C@@H](CC)[C@H](C(=O)CO)[C@@]1(C)CC2 IJLXLZGJDSJGIQ-BILPMHSYSA-N 0.000 claims description 6
- RCOWGILQXUPXEW-FUSOFXSQSA-N (8S,11R,13S,14S,17R)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-[(Z)-3-hydroxyprop-1-enyl]-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]2(O)\C=C/CO)[C@]2(C)C1 RCOWGILQXUPXEW-FUSOFXSQSA-N 0.000 claims description 6
- VHZPUDNSVGRVMB-RXDLHWJPSA-N (8S,11R,13S,14S,17S)-11-(4-acetylphenyl)-17-hydroxy-13-methyl-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(C(=O)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@@]2(O)C(F)(F)C(F)(F)F)[C@]2(C)C1 VHZPUDNSVGRVMB-RXDLHWJPSA-N 0.000 claims description 6
- GJMNAFGEUJBOCE-MEQIQULJSA-N Asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 claims description 6
- 229950001701 Lilopristone Drugs 0.000 claims description 6
- 229950001947 Lonaprisan Drugs 0.000 claims description 6
- 210000004072 Lung Anatomy 0.000 claims description 6
- 206010027191 Meningioma Diseases 0.000 claims description 6
- 229950005444 Telapristone Drugs 0.000 claims description 6
- 238000003364 immunohistochemistry Methods 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 5
- 210000004556 Brain Anatomy 0.000 claims description 5
- 229960004679 Doxorubicin Drugs 0.000 claims description 5
- 210000002307 Prostate Anatomy 0.000 claims description 5
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 5
- 230000002611 ovarian Effects 0.000 claims description 5
- 201000007954 uterine fibroid Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- QSFGZNVRVZHUGV-UHFFFAOYSA-N 4-[3-cyclopropyl-5-methyl-1-(methylsulfonylmethyl)pyrazol-4-yl]oxy-2,6-dimethylbenzonitrile Chemical compound C1CC1C1=NN(CS(C)(=O)=O)C(C)=C1OC1=CC(C)=C(C#N)C(C)=C1 QSFGZNVRVZHUGV-UHFFFAOYSA-N 0.000 claims description 3
- 229940035295 Ting Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 108010005144 Bevacizumab Proteins 0.000 claims description 2
- 229960004562 Carboplatin Drugs 0.000 claims description 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004397 Cyclophosphamide Drugs 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 108010010691 Trastuzumab Proteins 0.000 claims description 2
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims description 2
- 229940045698 antineoplastic Taxanes Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 238000010166 immunofluorescence Methods 0.000 claims description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- HKVAMNSJSFKALM-WDSGEKFTSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-WDSGEKFTSA-N 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- 101710037934 QRSL1 Proteins 0.000 claims 1
- 230000000259 anti-tumor Effects 0.000 claims 1
- 108091007906 nuclear progesterone receptors Proteins 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 description 38
- 201000011510 cancer Diseases 0.000 description 34
- 238000010186 staining Methods 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 20
- 239000000583 progesterone congener Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 17
- 238000004166 bioassay Methods 0.000 description 14
- 206010014733 Endometrial cancer Diseases 0.000 description 13
- 229940088597 Hormone Drugs 0.000 description 13
- 239000005556 hormone Substances 0.000 description 13
- 230000001413 cellular Effects 0.000 description 11
- 210000004881 tumor cells Anatomy 0.000 description 11
- 230000004913 activation Effects 0.000 description 9
- 229920001276 Ammonium polyphosphate Polymers 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- 239000012188 paraffin wax Substances 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 210000002325 Somatostatin-Secreting Cells Anatomy 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000038129 antigens Human genes 0.000 description 6
- 108091007172 antigens Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 102000015694 estrogen receptors Human genes 0.000 description 6
- 108010038795 estrogen receptors Proteins 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 230000002055 immunohistochemical Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 230000001833 anti-estrogenic Effects 0.000 description 5
- 229960000074 biopharmaceuticals Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000328 estrogen antagonist Substances 0.000 description 5
- 230000003054 hormonal Effects 0.000 description 5
- 230000003211 malignant Effects 0.000 description 5
- 108010045030 monoclonal antibodies Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- 230000001809 detectable Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 102000005614 monoclonal antibodies Human genes 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000000865 phosphorylative Effects 0.000 description 4
- 239000002379 progesterone receptor modulator Substances 0.000 description 4
- 229940095745 sex hormones and modulators of the genital system Progesterone receptor modulators Drugs 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004575 stone Substances 0.000 description 4
- 229940046836 Anti-estrogens Drugs 0.000 description 3
- 230000036912 Bioavailability Effects 0.000 description 3
- 210000003483 Chromatin Anatomy 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 229940072417 Peroxidase Drugs 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 108090000437 Peroxidases Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 230000003042 antagnostic Effects 0.000 description 3
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 3
- 230000035514 bioavailability Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229960000060 monoclonal antibodies Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- 229940046844 Aromatase inhibitors Drugs 0.000 description 2
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 2
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 2
- 210000004696 Endometrium Anatomy 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229940030490 PROGESTOGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229940095055 Progestogen systemic hormonal contraceptives Drugs 0.000 description 2
- 101700082488 SPRM Proteins 0.000 description 2
- 108010085012 Steroid Receptors Proteins 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000001594 aberrant Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003388 anti-hormone Effects 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 230000002254 contraceptive Effects 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 229940046079 endocrine therapy drugs Progestogens Drugs 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 108091008117 polyclonal antibodies Proteins 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000001072 progestational Effects 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 102000005969 steroid hormone receptors Human genes 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- MNUOZFHYBCRUOD-UHFFFAOYSA-N 3-hydroxyphthalic acid Chemical compound OC(=O)C1=CC=CC(O)=C1C(O)=O MNUOZFHYBCRUOD-UHFFFAOYSA-N 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 241000501754 Astronotus ocellatus Species 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- 208000000409 Breast Neoplasms Diseases 0.000 description 1
- WUEMPJNONXHVNQ-UHFFFAOYSA-N C=CCCC(C=CCCCCCCCCCC)=O Chemical compound C=CCCC(C=CCCCCCCCCCC)=O WUEMPJNONXHVNQ-UHFFFAOYSA-N 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229940011871 Estrogens Drugs 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 230000035520 G1 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 210000002816 Gills Anatomy 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- WZUVPPKBWHMQCE-VYIIXAMBSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@@]2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-VYIIXAMBSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 101710009221 LD Proteins 0.000 description 1
- 208000001791 Leiomyomatosis Diseases 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M Malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108010093413 Prophet of Pit-1 protein Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002547 anomalous Effects 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000711 cancerogenic Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229930002875 chlorophylls Natural products 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000003260 fluorescence intensity Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000001744 histochemical Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 230000000415 inactivating Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 230000002297 mitogenic Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000001338 necrotic Effects 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000034918 positive regulation of cell growth Effects 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 150000003146 progesterones Chemical class 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
Abstract
Discloses an in vitro method of predicting the efficacy of one or more anti-progestin(s) on a tumour or suspected tumour comprising: a) identifying progesterone receptor positive cells in a tissue sample suspected of being tumorigenic or cancerous from a patient; b) determining the degree of focal distribution of the progesterone receptor in nuclei of the progesterone positive cells from the tissue sample; and c) determining whether the degree of focal distribution in the tissue sample is greater than about 5% of the progesterone receptor positive cells. Also discloses related use of an anti-progestin composition in the manufacture of a medicament for treating a tumour susceptible to growth inhibition by one or more anti-progestin, a method of screening a drug candidate for the ability to decrease focal distribution of the nuclear progesterone receptor, and a system for classifying a tumour as being susceptible for treatment with an anti-progestin. distribution of the progesterone receptor in nuclei of the progesterone positive cells from the tissue sample; and c) determining whether the degree of focal distribution in the tissue sample is greater than about 5% of the progesterone receptor positive cells. Also discloses related use of an anti-progestin composition in the manufacture of a medicament for treating a tumour susceptible to growth inhibition by one or more anti-progestin, a method of screening a drug candidate for the ability to decrease focal distribution of the nuclear progesterone receptor, and a system for classifying a tumour as being susceptible for treatment with an anti-progestin.
Description
METHODS AND SYSTEMS FOR FYING AND TREATING ANTI-
PROGESTTN SENSITIVE TUMORS
BACKGROUND
This application claims priority to US. Provisional Patent Number
61/542,931, filed on October 4, 2011, the disclosure of which is incorporated by
reference herein in its entirety.
The progesterone receptor (PR) is present in cells in two major isoforms,
PR—A and PR-B. In the presence of a bound progestin ligand, such as terone, the
PR is phosphorylated at specific sites, dimerizes, forms a complex with a number of
different cellular elements (e.g., p300 and the steroid receptor coactivator), and binds to
specific DNA sequences known as progesterone responsive elements (PRES) to initiate
DNA transcription into RNA. The PR-ligand complex also attracts numerous other co~
activators and co—repressors, which form the cellular elements which in turn transcribe
particular genes. These PR complexes (also referred to as foci) can be ized in the
nuclei of cells which contain the progesterone receptor as fluorescent aggregates using
immunohistofluorescence ques and as dense and dark stained nuclear aggregates
using the immunohistochemistry techniques described in this patent.
In premenopausal women, during the proliferative phase (the first part of
the menstrual cycle) when estrogen is the nt hormone and progesterone is
lly secreted, staining of normal endometrial cells for PR—A and PR—B (e.g., using
immunofluorescent techniques and confocal microscopy) s a diffuse progesterone
receptor nuclear staining n. In the secretory phase (the second part of the menstrual
cycle) when progesterone is the dominant e, using the same immunofluorescent
techniques and confocal microscopy, staining for PR—A and PR—B s as readily
detectable fluorescent nuclear foci.
RNA transcription inhibitors have been shown to prevent formation of PR
foci, and 26S proteasome tors have been shown to disrupt the PR nuclear foci. It is
therefore believed that the presence of PR foci in cells corresponds to active
transcriptional complexes, and indicates the activation of the PR and uent gene
expression. Conversely, diffuse nuclear ng or the absence of PR foci indicates the
presence of PR which is transcriptionally inactive. Upon exposure of normal breast and
endometrium tissues (which are physiologically responsive to progesterone) to progestin
ligands, a change from a diffuse nuclear staining pattern to focal subnuclear structures
can be observed, indicating the activation of the progesterone or.
Whereas estrogens are mitogenic (e.g., cause cellular proliferation) for
normal breast epithelial and endometrial cells, the effects of progestins are more
complex. In the endometrium, progestins inhibit estrogen—induced cell cycle progression
early in the G1 phase, whereas in the breast progestins may both stimulate and inhibit
eration. In normal breast tissue biopsies it has been shown that proliferative activity
is stimulated by progesterone (Am J Obstet l, 1997). This complexity has led to
confounding experimental observations in breast cancer. For example, progestogens
red—
appear to have a direct proliferative effect on breast cancer cell in vitro when phenol
free media is used. H. J. Kloosterboer,J. Steroid Biochem. Molec. Biol. Vol. 49, No. 46,
pp. 311—318, 1994. However, when the same contraceptive progestogens that induced
proliferation in breast cancer cell lines were studied in an en-dependent DMBA rat
breast cancer model, these togens inhibited tumor progression. Id. It has been
shown recently that many such in vitro experimental models are inadequate. See, _e_.g,,
Lange C. et al. Progesterone Receptor Action: Translating Studies in Breast Cancer
Models to Clinical Insights. Chapter 7 in Innovative Endocrinology of Cancer; 94—111
(2010). While progesterone-induced proliferation has been shown in these experimental
, the majority of erating cells were not sing the PR. Thus, these
models do not necessarily predict the efficacy of treatment with antiprogestins.
Malignant cells also exhibit nuclear PR foci, but they are different in size
and composition from the foci of normal cells. PR foci ed in cancer indicate a
specific role for the PR which is pertinent to the malignant nature of the cells. For
e, the genes activated by the PR in malignant (cancer) breast cells are different
than the genes ted by the PR in normal breast cells; in endometrial cancers PR foci,
but not PR levels, are associated with malignant characteristics; foci in cancer cells are
larger, which may be due to alterations in the chromatin remodeling which are common
in cancer, and; PR foci in breast cancer are observed regardless of hormonal status (e.g.,
in the presence and absence of circulating terone in premenopausal and post-
menopausal women respectively). PR foci have been observed (e.g., using
immunofluorescent techniques and confocal microscopy) in the tumor cells of
approximately 50% of PR—receptor positive human breast cancer biopsies. Other
t’s tumor samples exhibited a e PR nuclear ng pattern in the tumor cells
using immunofluorescent techniques and confocal microscopy, indicative of a non-
activated or non—functional form of the PR.
The majority of breast cancers can be treated with hormonal treatments
(i.e., anti-estrogens or aromatase inhibitors), which are currently some of the most
effective medications used in breast cancer therapy. Hormonal treatment is usually
indicated based on the identification of hormone receptors within the cancer cells.
Onapristone (ONA) is an anti-progestin drug which was originally developed for
contraceptive use. However, it has demonstrated substantial activity in advanced breast
with breast
cancer, with a 10% response rate in a study of 101 poor prognosis patients
cancer in whom prior hormonal therapy had failed (e.g., breast cancer progressed despite
the patient receiving the antiestrogen tamoxifen). In a small breast cancer study using
DNA as a first line hormone treatment, ONA produced a 56% objective se rate, an
cy in the upper range of the best available treatments in this disease. ONA binds to
the PR, does not induce PR phosphorylation and does not allow the PR to dimerize. The
PR-ONA complex binds weakly, or not at all, to its target DNA segment and therefore
does not activate the chromatin remodeling which is a necessary s for DNA
transcription. In in vitro systems, DNA has been shown to reverse the PR nuclear
aggregates produced by binding of an artificial ligand to the PR. Gene activation studies
have consistently shown that, while progestins and other rogestins activate
progesterone sive genes, DNA has minimal activation (i.c., 3 genes).
In addition, DNA is a pure PR antagonist at concentrations which can be
logically achieved. ONA does not interfere with other steroid receptors and does
not increase estrogen secretion in human subjects, which is an undesirable side—effect
breast cancer y exhibited by other anti-progestins such as mifepristone.
While onapristone has previously been igated as a potential
therapeutic agent for breast cancer, its development was stopped due to toxicity concerns.
Robertson et al., Onaprz'stone, a Progesterone Receptor Antagonist, as Zine Therapy
in Primary Breast Cancer European J. of Cancer 35(2) 214—21 8 (1999). It is important to
identify the subset of the patients with tumors most likely to respond and equally as
important to identify the subset of the patients with tumors least likely to respond to
treatment with DNA and other anti-progestins. Identifying these subsets of patients will
allow those patients with APF access to a potentially effective cancer treatment and will
avoid exposing patients with those cancers for which DNA or other anti—progestins may
not provide benefit to unnecessary toxicity.
Currently, only the ce or absence of the estrogen or progesterone
whether to use an endocrine
receptor is ered when making therapeutic decisions on
treatment in certain s (e.g., breast cancer). ingly, conventional assays for
PR classify the tumors from patients with cancer into two categories: PR—positive or PR—
negative. One type of assay quantitates the amount of PR per total protein of the cell.
These methods can be automated and are quantitative, but are not satisfactory with
respect to accuracy, sensitivity and analysis of cellular subnuclear receptor structures.
second type of assay includes immunohistochemical s using formalin fixed tissue
specimens and fluorescent or chromophore labeled monoclonal antibodies targeting the
receptor (either an antibody for each of PR—A and PR—B, or a single antibody that
recognizes both). With histochemical methods, any microscopically detectable
r staining reaction in more than a certain percentage of cells (typically 2 1%), is
reported as being PR positive as per professional y guidelines. Typically, a clinical
cut off of 210% ER or PR positive cells is used to make therapeutic decisions regarding
the use of anti-hormone treatments. No consideration is given to the pattern of cellular or
nuclear staining. Relative ng intensity (i.e., low, medium, or high) is also use as a
qualitative measure of hormone receptor positivity. This second type of assay is more
labor ive and it is not standardized. Typically, low magnification microscopic
examination is used for the IHC analysis to fy the presence of the hormone receptor
(either estrogen receptor (ER) or PR). Using conventional methods, no analysis of
cellular distribution is done other then an estimate of the percentage of the tumor cells
expressing the identified hormone receptor. Analysis of the subnuclear distribution
pattern of the PR requires high powered copy. In st, high powered
microscopy is not needed for standard IHC determination of hormone receptors in tumor
tissue. These tional methods of hormone receptor determination are thus unable
to provide information regarding subnuclear PR distribution.
tins have complex actions in the breast and other hormone sensitive
tissues by targeting ct cells and having indirect effects on cells not expressing the
PR. PR foci complexes are not qualitatively the same in normal tissue and cancerous
tissue, and they do not necessarily activate the same progesterone receptor associated
genes. ble clinical data does not fully t the position that conventional
techniques for identifying hormone receptor positive cells are predictive of anti-hormone
efficacy, whether it be for anti—estrogen or anti—progestin directed treatments. tly,
the decision to utilize a hormone treatment (e.g., antiestrogens or aromatase inhibitors)
for patients with breast cancer and other e sensitive tumors is based on the simple
presence of hormone-receptors in tumor samples. The presence of e receptors
(ER or PR) does not fully predict for response to hormone treatment, as only 50—60% of
hormone-receptor positive tumor cases are expected to benefit from treatment.
There is a need for a consistent method for predicting the efficacy of DNA
and other anti—progestins with respect to heterogeneous “naturally occurring” tumors.
Further, there is a need for an assay which is predictive of therapeutic cy of DNA
and other anti—progestins against the cancers in individual patients.
SUMMARY
An important question pertinent to rogestin treatment is how to
fy activated PRs that are relevant clinical therapeutic targets. The present
exemplary methods are aimed at characterizing PRs that are present in a functional
(activated) state in the human tumor tissue routinely obtainable in the al g. As
antagonizing non—active PR with a c anti-progestin is therapeutically pointless, the
with
present methods provide new and critical information to guide treatment of patients
anti—progestins. Such a predictive diagnostic test would provide (1) consistent methods
to support therapeutic decision—making with respect to DNA and other anti—progestins,
(2) guide selection of individual patients and patient populations that are likely to respond
to treatment, and (3) exclude those individual ts that are least likely to respond or
benefit from an anti-progestin treatment.
In one aspect, a method for identification and treatment of a subset of
with an anti-
progesterone receptor (PR) positive tumors most susceptible to treatment
progestin such as onapristone (DNA) is provided. Progesterone or positive tumors
exhibiting a dense, focal PR nuclear distribution pattern, as described herein, are more
susceptible to treatment with anti—progestins such as stone. Results from in vitro
homogeneous, experimental models are not necessarily predictive of the properties of
lly-occurring heterogeneous .
In another aspect, a method of inhibiting the growth of a tumor susceptible
to growth inhibition by anti—progestins is provided. A tissue sample suspected of being
tumorigenic or cancerous can be obtained from a patient. Progesterone or positive
cells in the tissue sample can be fied. The degree of distribution of the progesterone
tissue sample can then
receptor foci in nuclei of the progesterone positive cells from the
be determined and an anti—progestin can be administered to the patient if the degree of
focal distribution in the tissue sample is greater than about 5% of the progesterone
receptor positive cells.
These patients are more likely to benefit from treatment with an anti—
tin that inactivates activated progesterone foci (APP) (e.g., DNA) and prevents
further ion of APF than patients whose tumors do not express activated PR. The
non—activated form of the PR is lly seen as diffuse nuclear PR staining.
Inactivation of the APF by an rogestin may occur by any of a variety of
isms, including dissociation of the foci and inhibition of activation of the foci
without substantially altering their structure. In one aspect, APF formation can be
inhibited or prevented by an anti-progestin through several mechanisms. For example,
onapristone may not allow the individual progesterone receptors to dimerize and t
the PR from being phosphorylated at the ligand phosphorylation sites. The PR-ONA
x may bind weakly, or not at all, to its target DNA segment (PRES) and fail to
induce the chromatin remodeling which is a necessary process for DNA transcription. In
another example, other anti—progestins may allow the PR to dimerize and form complexes
with co-activators or co—repressors which do not induce DNA transcription.
In this example, DNA binding may occur at the PRE, but transcription
does not occur. Identification of APF may inform the decision of any anti—progestin
treatment as long as the agent interferes with the PR pathway. In one aspect,
identification of APF determines the status of the PR pathway as activated or not. For
example, the use of mifepristone, or any progestin that complexes with PR and binds to
the DNA, could be informed by the identification of APF. The activity of other agents,
including those which would inhibit PR phosphorylation and thus interfere with PR
activation, would be predicted by the presence of APF in various cancers. Thus,
identification of APF could be used to inform ent recommendations for various
classes of compounds which act by inhibiting the function of the PR.
Patient tumors that do not s activated PR foci (APP) may include
those that are PR—negative by the conventional assay, or those that are PR—positive by the
conventional assay. In one aspect, any cancer which exhibits APF is a candidate
for treatment with such anti—progestins, ing breast, brain, meningiomas, prostate,
ovarian, endometrial, uterine leiomyoma, lung, and uterine s. Pulmonary
leiomyomatosis which has yet to be formally classified as a cancerous condition
would also be likely to benefit if APF is expressed in the abnormal tissue. In another
aspect, benign tumors not able with standard treatment, but presenting APF,
can be treated by an antiprogestin as the presence of APF indicates that the tumor is
driven by aberrant activation of PR, i.e. by the progestin pathway.
Another aspect provides a method of treating patient with a tumor
susceptible to growth tion by anti-progestins by obtaining a tissue sample
suspected of being tumorigenic or cancerous from a patient and exposing the tissue to
an anti-progesterone receptor antibody. Progesterone receptor positive cells in the
tissue sample can be identified. The degree of focal g distribution of the
terone receptor in nuclei of cells from the tissue can be determined. If the focal
binding distribution is r than about 5% of the progesterone receptor positive
cells in the tissue sample, an anti-progestin is administered to the patient in a dosage
range of about 10 to about 200 mg per day depending upon the potency,
bioavailability, and safety profile of the antiprogestin.
[0019B] Another aspect provides an in vitro method of predicting the efficacy
of one or more anti-progestin(s) on a tumor or suspected tumor comprising: a)
identifying progesterone receptor positive cells in a tissue sample suspected of being
tumorigenic or cancerous from a patient; b) determining the degree of focal
distribution of the progesterone receptor in nuclei of the progesterone positive cells
from the tissue sample; and c) determining whether the degree of focal distribution in
the tissue sample is greater than about 5% of the progesterone receptor ve cells.
[0019C] Another aspect provides the use of an rogestin composition in the
cture of a medicament for treating a tumor susceptible to growth inhibition by
one or more anti-progestin(s), wherein the susceptibility is determined by :a) exposing
a tissue sample ted of being tumorigenic from a patient to an anti-progesterone
receptor antibody; b) identifying progesterone receptor positive cells in the tissue
sample; and c) determining the focal binding distribution of the progesterone receptor
in nuclei of cells from the tissue such that if the focal binding bution is greater
than 5% of the progesterone or positive cells in the tissue sample with an A or
AD binding n, the tumor is determined to be susceptible to growth inhibition by
one or more anti-progestin(s), the anti-progestin is in a dosage range of about 10 to
about 200 mg per day.
[0019D] Another aspect provides the use of an anti-progestin ition in the
preparation of a ment for the treatment of a tumor susceptible to growth
inhibition by one or more anti-progestin(s), wherein the tumor is identified as
susceptible to growth inhibition by one or more anti-progestin(s) wherein a) a tissue
sample suspected of being tumorigenic from a patient is exposed to an anti-progestin
receptor antibody; b) identifying progesterone receptor positive cells in the tissue
sample; and c) determining the focal binding distribution of the progesterone or
in nuclei of cells from the tissue n if the focal binding distribution is greater
than 5% of the progesterone or positive cells in the tissue sample with an A or
AD binding pattern.
[0019E] In yet a further aspect there is provided the use of onapristone in the
manufacturing of a medicament for the treatment of a tumor comprising: identifying a
patient exhibiting greater than about 5% focal distribution of the progesterone
receptor in the cell nuclei of progesterone receptor positive cells in a tumor tissue
biopsy; wherein the onapristone is in an amount from about 10 to about 200 mg per
day.
[0019F] In another aspect, there is provided the use of onapristone in the
preparation of a medicament for the treatment of a tumor in a patient, wherein the
tumor is susceptible to growth inhibition by onapristone, and wherein the t is
identified as exhibiting greater than about 5% focal distribution of the progesterone
receptor in the cell nuclei of progesterone receptor positive cells in a tumor tissue
[0019G] In another aspect, there is provided a method of screening a drug
candidate for the ability to decrease focal bution of the progesterone receptor in
the nuclei of progesterone receptor positive cells in a tumor comprising:, ng a
first tumor tissue specimen from the tumor to a drug ate, exposing the first and
at least a second tumor tissue specimen from the same tumor to anti-progesterone
receptor antibodies, determining the degree of focal distribution of progesterone
receptors in the nuclei of the progesterone receptor positive cells from the tumor
tissue specimens, and determining if the focal distribution of the progesterone
receptor in the tumor tissue specimen exposed to the drug candidate is decreased
compared to tumor tissue specimens not exposed to the drug ate, wherein if the
drug candidate decreases the focal distribution of the progesterone receptor in the
progesterone receptor positive cells of the tissue specimen exposed to the drug
candidate, the drug ate is capable of decreasing focal distribution of the
progesterone receptor in progesterone receptor positive cells of the tumor.[0019G]
In another aspect there is provided a system for classifying a tumor susceptible
for treatment with an anti-progestin, comprising a tissue sample and at least one
antibody or antibody binding fragment capable of detecting the progesterone receptor
wherein the antibody or antibody binding fragment is used to determine the degree of
focal distribution of the progesterone receptor in the terone receptor positive
nuclei of cells from a tumor tissue specimen and wherein the tumor is tible to
treatment with an anti-progestin if the degree of focal bution in the cell nuclei of
the progesterone positive cells is greater than about 5%.
In r aspect, the tissue is a en of a tumor tissue selected
from the group consisting of , brain, meningiomas, prostate, ovarian,
endometrial, uterine leiomyoma, lung, and uterine tissue.
In another aspect, the presence or e of focal distribution is
detected by fluorescence, a colorimetic reaction (e.g., an enzymatic reaction), imaged
with a counter staining antibody (e.g., chromophore), ctivity, and Western blot
(e.g., differential phosphorylation of the PR).
In yet another aspect, the anti-progestin is selected from the group
consisting of onapristone, lonaprisan, mifepristone, PF-02413873, telapristone,
lilopristone, ORG2058, asoprisnil, and ulipristal.
The presence of active progesterone receptor focal distribution is
indicated by a degree of nuclear focal distribution of r than about 5% of the
terone receptor positive cells. In another aspect, a tumor may be heterogeneous
with t to
[Text continued on page 9]
focal distribution and exhibit an active g pattern (A) with distinct progesterone
receptor foci, a diffuse binding pattern (D) without distinct progesterone receptor foci, or
of the tumor.
a mixture of an A pattern and a D pattern (AD) in various areas
In any of the foregoing aspects, when focal distribution (A or AD pattern)
is present, the intensity or density of such focal distribution may be quantitated. For
example, progesterone receptor dies may be radiolabeled, fluorescently labeled,
imaged with a counter staining antibody (chromophore), imaged with a colorimetic
reaction (e. g., an enzymatic reaction), or labeled in another manner where the intensity of
the label can be measured and quantified.
FIGURES
FIGS. 1A and 1B shows exemplary immunohistochemical brown nuclear
staining ns in human breast cancer samples derived from formalin-fixed and
paraffin—embedded biopsies using antibodies directed to the progesterone receptor;
FIGS. 2A and 2B show exemplary green nuclear staining patterns in
human breast cancer samples derived from formalin-fixed and paraffin-embedded
biopsies using antibodies directed to the progesterone receptor;
FIGS. 3A and 3B show exemplary immunohistochemical brown nuclear
staining patterns with HES ound counterstaining in human breast cancer samples
derived from invfixed and paraffin—embedded biopsies using dies directed to
the progesterone receptor; and
shows the percent of breast cancer samples positive for PR—A and
PR—B for three binding patterns, A, AD, and D.
ED DESCRIPTION
Before describing several exemplary aspects described herein, it is to be
understood that the invention is not limited to the details of construction or process steps
set forth in the following description. The aspects described herein are capable of being
ced or being d out in various ways.
As used herein, the phrases "treating a tumor" and "treatment of a tumor"
mean to inhibit the replication of tumor cells, inhibit the spread of the tumor, decrease
tumor size, lessen or reduce the number of tumor cells in the body, or rate or
alleviate the symptoms of the disease caused by the tumor, decrease the growth of the
tumor (increase the time it takes the tumor to progress) or improve the survival of the
patient when death is due to the cancer or secondary effects of the cancer. The term also
es treatment of cancer. Tumors include both cancers and non—cancerous tumors.
The treatment is considered therapeutic if there is a decrease in mortality and/or
morbidity, improvement of tumor-related symptoms, or there is a decrease in disease
burden as may be manifested by reduced numbers of tumor cells in the body, decreased
tumor size or improvement in the time to progression, ement of progression free
survival or ement of e free survival.
As used herein, the term “APP—active rogestin” and its equivalents
refer to an anti—progestin drug which exhibits an ability to dissolve or dissociate activated
PR foci (APF) in the nuclei of cells or inhibit the formation of APF in the nuclei of cells,
indicating that its ism of action is via the PR activation pathway of the cell.
The terms “APP-positive”, “PR foci positive”, “activated PR”, “PRs in a
functional state” and the like refer to the presence of progesterone receptor aggregates in
the nuclei of cells.
The term “focal distribution” refers to the distribution of “foci” (i.e.,
aggregation of progesterone receptors) in the nuclei of terone positive cells.
Speckled or hyperspeckled pattern are terms that can be used referring to steroid nuclear
receptor foci n in biology.
The term “degree of focal bution” refers to the relative amount of PR
foci present in the nuclei of progesterone positive cells. The degree of focal distribution
can be determined quantitatively or qualitatively.
For example, the use of a colorimetric, enzymatic, or radiolabeled ligand
such as a progesterone or antibody, can be used to bind to progesterone receptors in
cell nuclei. The degree of focal distribution can be determined quantitatively, for
example, by measuring color intensity, fluorescence or fying the level of
radioactivity emitted by the labeled antibody. The degree of focal distribution can
determined qualitatively by comparing the intensity of binding between a control sample
and a d sample using a light microscope at an appropriate magnification or
techniques including, but not d to, DNA rray, n profiling,
radiolabeling, or other surrogates for measuring APF.
The term “ diffuse pattern” refers to a finely granular pattern which is
indicative of the absence of focal distribution.
The term “progestin” refers to a natural or synthetic progestational
substance that mimics some or all of the actions of progesterone, also referred to as
progesterone receptor modulators (PRM) or ive progesterone receptor modulators
(SPRM).
The term “anti—progestin” refers to a substance that inhibits the formation,
transport, or action of or inactivates progestational agents, including, but not limited to,
stone, lonaprisan, mifepristone, PF—024l3873, telapristone, lilopristone, ORG2058,
asoprisnil, and ulipristal. A PRM or SPRM may have some anti—progestin properties, and
be considered an rogestin or a progestin depending on the context of use.
The term “antibody” or “antibodies” refers to a protein which is capable of
specifically binding to an antigen and includes any substance, or group of substances,
which has a specific binding affinity for an antigen to the exclusion of other substances.
Generally, the term ody” includes polyclonal antibodies, monoclonal antibodies,
antibodies derived from humans or animals, humanized antibodies (e. g., non-binding
portions derived from a human, binding portions derived from an animals) and fragments
The terms “anti—PR-A” and “anti—PR—B” dies refer to antibodies
ed to isoforms of the progesterone or — PR—A and PR—B respectively. Anti—
PR—AB” refers to an antibody capable of binding to both PR—A and PR—B. Specific
antibodies suitable for use in accordance with aspects herein include, but are not limited
to, PgR636 and PgR1294 (M. Press, et a1. (Steroids (2002) 67:799—813)), Novacastra
clone 16, clone SAN27, clone 1A6, Dako clone PgR636, Ventana, clone 1E2, Novus
Biologicals Progesterone Receptor [p ] Antibody Clone 1064-132; Novus
icals Progesterone Receptor [p Serl90] Antibody Clone EP1516Y, Novus
Biologicals Progesterone Receptor [p Ser294] Antibody Clone 608, Abcam Progesterone
or [p Ser400] dy Ref ab60954, and Genetex terone or [p
Ser554] Antibody Ref. GTXl 18987.
The term “administer” refers to providing a drug or drugs, prescribing one
or more drugs, or g one or more drugs on a formulary. The term “providing” refers
to dispensing the drug ly to patient through any suitable route of administration
(e.g., oral, injection, enous, intramuscular, and transdermal etc.) or providing
instructions to a patient to do the same.
One aspect provides a method of inhibiting the growth of a tumor
tible to growth inhibition by anti-progestins by obtaining a tissue suspected of
being genic from a patient and determining the degree of focal distribution of anti—
terone receptor in nuclei of cells from the . If the degree of focal distribution
is greater than about 5%, an ant-progestin (e.g., onapristone, lonaprisan, mifepristone,
PF—024l3873, telapristone, lilopristone, ORG2058, asoprisnil, and ulipristal) can be
administered to the patient.
While the role of PR, progestins and anti—progestins in breast and other
cancers has previously been studied, the results have been inconclusive leading to
difficulties in diagnosing and treating patients. Multiple models have shown the
numerous and complex interactions of species, strains, cancer type, carcinogens, and
tumor environment among other factors. Without being bound by theory, the PR may be
pathologically activated with altered physiological properties affecting the activation
potential of the ligand resulting in abnormal or uncontrolled stimulation of cell growth
and proliferation. However, the most commonly studied models originate from a small
number of original tumors, and therefore do not accurately represent the physiological
variability between tumor types or the tumors of different patients. That is, the limited
number of cancer models is insufficient to cover the complexity of heterogenic cancers in
a human population.
Studies of the formation of PR foci have been used to test compounds for
their y to induce PR translocation from the cytoplasm to the nucleus in genetically
engineered cell lines. These assays, such as the Thermo Scientific PR (Progesterone
Receptor) Redistribution® Assay, use image is and fluorescence microscopy to
quantitate nuclear accumulation of PR in the presence of the test compound. In contrast,
s ed herein are designed for analysis of PR foci in primary tumor tissue,
irrespective of the presence of a PR ligand or a drug. In one aspect, the exemplary
methods described herein relate to the presence of PR foci in the nuclei of cells in
lly-occurring tumors indicating an anomaly that can be used to t the efficacy
in that patient of an anti-progestin that has PR antagonist properties. In another aspect,
the characterization of constitutively ted PR in the clinic has now been found to
indicate that tumors and cancers are susceptible to treatment with anti-progestins,
including onapristone.
Onapristone, (e.g., (88,1 lR,l3R,14S,l7S)—ll—[4~(dimethylamino)phenyl]—
17—hydroxy-17—(3—hydroxypropyl)—l3—methyl—l,2,6,7,8,1 1,12,14,15,16—
decahydrocyclopenta[a]phenanthren—3-one) has the following chemical structure:
WO 52652
Other anti-progestins include: progestational 3—(6,6—ethy1ene—17B-
hydroxy—3—0xo—17A—pregna—4-ene—17A—YL)pr0pionic acid G—lactones, 3~(6,6-ethy1ene—
17.beta.-hydroxy0X0—17.alpha.—pregna—4—ene-17.a1pha.-y- 1)propionic acid gamma.-
lactone and the following:
Mifepristone
(108,1 1 S, 148,1 5 S,17R)—17-[4-(dimethylamino)pheny1]—14—hydroxy—1 5-methy1—14—(prop-
1 ~yn—1—y1)tetracyclo[8.7.0.0"{2,7} .O"{ 1 heptadeca—1,6-dien—5 —one
/‘ /'
ff “Md/"V g x'
l 0 {479C
K.” w ,/C
“113/" 3/ W
- X
‘_4_./"\-\R , a“ /’L“ //
1 ‘1“ r
.. ,4’ x _/
n x ,,
Lilopristone
(1 1-beta,17—beta,17(2))—ropeny1);estra—4,9—dien—3—one,1 1—(4—(dimethylamino)phenyl)—1 7—
hydroxy—17—(3 -hydr0xy—1-p;1 1B~[4-(Dimethylamin0)pheny1]-17B—hydroxy-17—[(Z)~3 —
hydroxy— 1 nyl]estra—4,9—dien-3 -0ne
[0049} ORG2058
(8R,9S, 1 OR, 1 3 S,14S,16R,17S)-16—ethy1-17—(2—hydroxyacety1)—13-methy1-2,6,
7,8,9,10,1 1 ,12,14,15,16,17—dodecahydrO—1H—cyclopenta[a]phenanthren—3~0ne
0x“. .‘f
H m I /\"k
/"'~ ‘1’ -r& w: m.‘1 ‘x
" “x. ’
1 1. 0”;
7:31;“?N.‘ #5333? “I
Q ”xxx",
Lonaprisan
(88,1 1R,13S,14S,17S)(4-acety1pheny1)~17~hydroxy~13—methy1—17-(1,1,2,
2,2-pentaflu0roethy1)—1,2,6,7,8,1 1,12,14,15,16—decahydrocyclopenta[a]phenanthren—3-
Asoprisnil
(8 S, 1 1 R, 1 3 S,14S,17S)—1 1-[4-[(E)-hydroxyimin0methy1]phenyl]—17—methoxy-17—
(methoxymethyl)—13-methyl—1,2,6,7,8,1 4,15,16—
decahydrocyclopenta[a]phenanthren—3-0ne
Ulipristal
(8 S, 1 1 R, 1 3 S, 1 4S, 17R)—17—acety1-1 1-[4—(dimethylamino)pheny1]—17—hydroxy—1 3 —methyl—
1,2,6,7,8,1 1,12,14,15,16—decahydrocyc10penta[a]phenanthren—3—one
,f"\ 42¢“\,, a ‘35
L l W
/ ix ”1" '\,._,x‘"g" 'J
l 1' W
x,» /’ ,x‘1
if” K55”,
0 \x‘w
PF-2413873
4-[3-Cyclopropyl—1—(rnesylmethyl)—5—methyl—1H-pyrazol—4—yl]oxy,—2,6-
dimethylbenzonitrile
/’/\’s
'ii"“‘:"~\ itQ
Prefix \
l 'N..._
(”f/":\QI//
i l‘
In another aspect, focal PR g es a more sensitive and
predictive test than currently-used conventional PR assays. ts fied in
conventional PR assays as PR—negative as well as those that are conventionally PR—
positive may test positive for focal PR nuclear binding and therefore be candidates for
treatment with anti—progestins such as onapristone. Thus, a patient previously identified
candidate for
as PR negative using previous methods would not have been considered a
WO 52652
treatment with rogestins such as onapristone. The presence of PR foci in ts
conventionally tested as PR~negative would explain the apparently anomalous result that
onapristone is active in some of these patients. Aspects described herein will therefore
make hormonal treatment potentially available to a greater number of patients with
that are classified as “triple
cancer, including potentially those patients with breast cancer
negative” (i.e., negative for estrogen or (ER), PR and Her2).
Exemplary suitable immunohistochemical methods for use in aspects
described herein are described by M. Press, et al. (Steroids (2002) 67:799—813) and M.
Nadji (Anatomic Pathol. (2005) —27) hereby incorporated by reference in their
entirety. By way of example, primary cancer tissue specimens for analysis may be
prepared as paraffin sections or fine needle aspiration smears of the cancer tissue as is
known in the art for conventional PR assays. If paraffin sections are used, the paraffin is
first melted by heating the slides, and dewaxed with xylene. Slides are then rehydrated in
decreasing grades of ethanol and exposed to an antibody, preferably a monoclonal
antibody that specifically binds to PR—A, PR—B, or both. Binding of the antibody is then
ed using any one of the methods known in the art for detection of antibody binding,
es of which are described below.
One exemplary suitable method for detection of binding of an antibody to
its target is a colorimetric assay, typically an enzymatic colorimetric assay. One such
method employs peroxidase to produce a colored stain visible under the light microscope.
Endogenous peroxidase in the tissue specimen is blocked using hydrogen peroxide and
nous biotin is d using a biotin—blocking reagent prior to tion with the
antibody or antibodies. If the primary antibody is a mouse antibody, it is subsequently
bound to a biotinylated antimouse immunoglobulin. Streptavidin-peroxidase ate is
added to bind the enzyme to the antibody—target complex. Color is developed by addition
of obenzidine and cupric sulfate. The tissue specimen may be counterstained with
fast green to increase visibility of the peroxidase stain.
Alternatively, a fluorescence method may be used to detect antibody
binding to PR—A, PR-B or both. In this case, a fluorescently—labeled primary antibody
under a fluorescence microscope.
may be bound to the PR target and detected directly
However, antibody to the PR
a method ing g of an unlabeled primary
followed by binding a fluorescently—labeled ary (e.g., antimouse immunoglobulin)
antibody to the primary antibody may reduce non—specific fluorescence. Any cent
label known for use in immunohistochemical assays may be used in the aspects described
herein, for example FITC (fluorescein isothiocyanate); fluorescein FITC 520 nm green
Alexa 488 515 nm green phycoerythrin PE 565 nm yellow; phycoerythrin—Texas Red
ECD 620 nm red; rythrin-cyanineS PC5 665 nm deep red; Peridinin chlorophyll
PerCP 670 nm deep red; phycoerythrin—cyanine 5.5 PC5.5 703 nm far red; rythrin-
cyanine 7 PC7 755 far red; E allophycocyanin APC 660 nm deep red; Allophycocyanin—
cyanine 7 APC-CY7.
Both monoclonal and polyclonal antibodies may be useful in aspects
described herein. A non-exhaustive list of suitable monoclonal antibodies is described by
M. Press, et al. supra, including two antibodies which are resistant to formalin fixation
and paraffin embedding (PgR636 and 4). Specific antibodies suitable for use in
accordance with s herein include, but are not limited to, PgR636 and PgRl294 (M.
Press, et a1. (Steroids (2002) 67:799—813)), Novacastra clone 16, clone SAN27, clone
1A6, Dako clone PgR636, Ventana, clone 1E2, Novus Biologicals Progesterone Receptor
[p Serl62] Antibody Clone 1064-132; Novus Biologicals Progesterone Receptor [p
Serl90] Antibody Clone EP1516Y, Novus Biologicals Progesterone Receptor [p Ser294]
Antibody Clone 608, Abcam Progesterone Receptor [p Ser400] Antibody Ref ab60954,
and Genetex Progesterone Receptor [p Ser554] dy Ref. GTXl 18987.
In one aspect, binding of the antibody to PR is detected by observation of
the stained slide under a light microscope or cence microscope as appropriate.
Magnification is typically about 200X or 400X to evaluate, for example, the percentage
of cells positive for binding to an dy. However, to improve sensitivity for ion
of APF it may be desirable to evaluate the slides at SOOX—lOOOX to facilitate study of
lear structures.
Samples that are apparently PR ve by microscopy may be evaluated
by flow cytometry to detect positive samples below the threshold of light or fluorescence
microscopy. If flow cytometry indicates rare positive cells, high magnification X800—
XlOOO microscopy may be used to study subnuclear structures and identify activated
terone or foci (APF). However, if the positive cells detected by flow
cytometry are too rare to be reliably detected by microscopy for is of APF, a
fluorescence—activated cell sorter (FACS) can be used to separate positive cells from the
cells in suspension based on their fluorescence (e.g., Sony Cell Sorter SH800, Siemens
Immulite 2000). As positive cells are concentrated but not damaged by this process, the
reliability and probability of sfully visualizing APF on subsequent microscopic
evaluation is substantially increased.
The presence or absence of APF in individual tumor cell nuclei may be
detected visually under a light or fluorescence microscope, or by any other appropriate
In one aspect, visual means
means, such as fluorescence or metric measurements.
for detection will be used. The results of staining may be quantitated by noting presence
or absence of APF, or by counting the number or tage of positive cells.
Alternatively, c characteristics of the ng may be quantitated. For example,
detection may include notation of whether or not focal binding in the form of APF is
accompanied by diffuse nuclear staining, quantitation of positive cells by number or
tage, and/or quantitation of intensity or number/density of APF. Quantitation of
APF density may be determined as the average number of foci/cell, or using an arbitrary
scale (e. g., “few”, “moderate” or “many”). Intensity may similarly be determined using
1—5. In another
an arbitrary scale, e.g., dium/high or a numerical scale such as
aspect, the results of the analysis of the patient’s tumor tissue will be compared to
positive and/or negative controls.
In one aspect, a tumor tissue specimen is judged as APP-positive when l—
100%, 5-100%, 25—100% or 50100% of the nuclei of progesterone positive cells in the
specimen exhibit APF. In yet another aspect, the eutic efficacy of an APF—active
anti—progestin may also be correlated with the intensity of APF staining or with the
number or density of APF, these parameters may also be used to ine the sensitivity
of the tumor to treatment with the APF~active anti—progestin. In general, and without
being bound by theory, the sensitivity of a tumor to treatment with APF-active anti—
progestin will se with increasing number or percentage of positive cells, increasing
intensity of APF and/or increasing number of APF in the cells of the tumor tissue
specimen.
In r aspects, methods for determining the sensitivity of a tumor to
APP—active anti-progestins may be either manual (e.g., visual detection using a
fluorescence microscope) or they may be automated or utomated using methods
for rapid scanning, detection and quantitation of colorimetrically— or fluorescentIy—labeled
tissue specimens. For example, a fully automated scanning and analysis system may be
developed and used in certain aspects. While manual selection of specific regions of the
tumor to be analyzed may be used in one aspect, (e.g., InScape® immunohistochemistry
3 Giralda
system ((e.g., InScape® immunohistochemistry system (Quest Diagnostics
APF in
Farms Madison, NJ 07940), an automated system for scanning and is of
cell nuclei can be used to provide automated specimen scanning and analysis of
the antigen—specific immunohistochemistry stained specimen. In r aspect, image
recognition can be used to create a digital image of the entire stained tissue section; An
antigen—specific computer algorithm can be used to analyze the results of the digital
image enting the whole specimen. In yet another , the software can
configured to distinguish foci from diffuse background staining in the nucleus, and
e fluorescence intensity and size of foci on a cell-by-cell or cluster—by—cluster
basis, repeating the s for each cell or cluster over the entire specimen. These
automated methods can, in certain aspects, result in ed accuracy by performing a
function that is not possible manually, with reduced cost. Full automation can also make
the test accessible to non—expert medical centers.
In one aspect, the decision whether to treat the patient based on the results
of the diagnostic assay is based on the number/percentage, intensity and/or density of
APF when they are present. Without being bound by theory, it is anticipated that the
efficacy of treatment with an APP-active anti-progestin will se with increasing
number or percentage of positive cells, increasing intensity of APF and/or increasing
number of APF in the cells of the tumor tissue specimen. Based on these parameters the
l practitioner may also determine the dosing, timing and length of treatment.
Accordingly, another aspect relates to use of an APF~active rogestin for treating an
sitive tumor.
The tumor to be fied or treated according to the above methods may
include any ous or non—cancerous tumor in which APF occur, and in which the
presence of APF can be determined. Such cancers or tumors include breast cancer, lung,
uterine cancer, e leiomyoma, ovarian cancer, prostate cancer, brain, and angiomas.
Benign tumors which can be identified or treated according to certain aspects include
meningiomas, 70% of which express PR by conventional analysis.
The APF-active anti-progestin of the foregoing methods may be any anti~
progestin drug having the ability to inactivate APF (for example by dissolving or
dissociating the aggregates or preventing formation of APF or forming inactive APF).
Such drugs include onapristone (DNA), but others with a similar mechanism of action are
also suitable for use in aspects bed herein.
Another aspect provides methods of identifying a tumor susceptible to
growth tion by anti-progestins by obtaining a tissue suspected of being tumorigenic
or cancerous from a patient and exposing the tissue to an anti—progesterone or
antibody. Progesterone positive cells in the tissue sample can be identified. The degree
of focal distribution of the progesterone receptor in nuclei of the progesterone positive
cells from the tissue sample can be determined and an antiprogestin can be administered
to the patient if the degree of focal distribution in the tissue sample is greater than about
% of the progesterone receptor positive cells.
In yet another aspect, a method of treating a patient with a tumor
tible to growth inhibition by anti-progestins is provided. The method ses
obtaining a tissue sample suspected of being tumorigenic from a patient and exposing the
tissue to an anti—progesterone receptor antibody. The progesterone receptor positive cells
in the tissue sample can be identified and the focal binding distribution of the
progesterone receptor in nuclei of cells from the tissue can be determined. If the focal
binding distribution is greater than 5% A or AD binding pattern of the progesterone
receptor positive cells in the tissue sample, an anti—progestin is administered to the t
in a dosage range of about 10 to about 200 mg per day depending upon the potency,
bioavailability, and safety profile of the anti—progestin.
In another aspect, the degree of focal distribution can be determined by
suitable method as discussed herein including immunochemical, fluorescence,
DNA microarray, protein profiling, radiolabeling, or other surrogates for measuring APP.
In r , the tumor tissue is selected from the group consisting of
breast, meningiomas, prostate, ovarian, endometrial, uterine leiomyoma, lung, and uterine
tissue.
In yet another aspect, the anti-progestin is selected from the group
ting of stone, lonaprisan, istone, PF—024l3873, telapristone,
istone, ORG2058, asoprisnil, and ulipristal.
In another aspect, the degree of focal distribution is determined by
identifying the binding pattern of progesterone receptor in the nuclei of progesterone
positive tissue cells. Heterogeneous tumors include cells which may have active
progesterone receptor foci or inactive progesterone receptor foci. Therefore, there may
be ar s containing active foci as shown by distinct clumps in the cellular
nuclei, and cellular regions which exhibit a more diffuse pattern.
For example, Figure 1 depicts two exemplary binding ns from brown
nuclear staining obtained with anti—progesterone antibodies in human breast cancer
samples formalin-fixed and paraffin—embedded tissue samples obtained from biopsies of
breast cancer patients. Figure 1A shows a diffuse, granular pattern (D) indicative of cells
which are not likely to be susceptible to treatment with anti-progestins. In contrast,
Figure 1B shows a mottled binding pattern (A) indicative of cells which are likely to be
susceptible to treatment with anti—progestins. A mixed pattern exhibits both A and D
patterns and is termed AD.
In another aspect, the anti—progesterone antibody is selected from the
anti—PR-B antibody, and a mixture of anti—PR-A
group consisting of anti—PR—A antibody,
and anti—PR~B antibodies, and bispecific R AB antibodies.
In yet another aspect, the anti—progestin is administered in an amount from
to about 200 mg per day depending upon the potency, bioavailability, and safety
profile of the anti—progestin.. t being bound by theory, it is believed that by
identifying patients with tumors that are susceptible to treatment with progestins, a lower
dose of the anti-progestin may be used resulting in a lower risk of toxic side effects.
Thus, than 5% focal
a lower dosage range can be used for patients exhibiting greater
distribution of the progesterone receptor. In one aspect, the A or AD classification could
result in different doses, while D pattern would indicate that treatment with an anti—
progestin treatment is not ted.
In yet another aspect, methods for screening mor drugs for the ability
to inactivate APF are provided. These methods are useful, for example, to identify
additional rogestins which may be candidates for use in treating of APP—positive
tumors according to the methods described herein. In one , the method provides a
method of screening a drug candidate for the ability to decrease focal distribution of the
cells in a tumor. At
progesterone receptor in the nuclei of progesterone receptor positive
least two tumor tissue specimens from the same tumor can be obtained. One tumor tissue
specimen can be exposed to a drug candidate. The tumor tissue specimens can then be
exposed to anti-progesterone receptor antibodies and the degree of focal bution of
cells from the
progesterone receptors in the nuclei of the progesterone receptor positive
tumor tissue specimens can be determined. If the focal distribution of the terone
receptor in the tumor tissue specimen exposed to the drug candidate is decreased
compared to tumor tissue specimens not exposed to the drug candidate, the drug
ate is capable of decreasing focal distribution of the terone receptor in
terone receptor positive cells of the tumor.
Another aspect provides a system for classifying a tumor susceptible for
treatment with an anti—progestin, comprising a tissue sample and at least one antibody or
antibody binding fragment capable of detecting the progesterone receptor. The antibody
or antibody binding fragment can be used to ine the degree of focal distribution of
the progesterone receptor in the progesterone or positive nuclei of cells from a
tumor tissue specimen. In another aspect, the tumor is susceptible to treatment with an
anti—progestin if the degree of focal distribution in the cell nuclei of the progesterone
positive cells is r than about 5%.
In another aspect, ing a decrease in detectable staining of the APF is
an tion of APF inactivating ty of the antitumor drug. Detecting no substantial
decrease in detectable staining of the APF is an indication of lack of APF inactivation of
the antitumor drug.
In another aspect, an tive anti—progestin may be used in
combination with additional hormonal treatment that does not act by an APF inactivation
mechanism (e.g., antiestrogens) to achieve improved therapeutic efficacy as compared to
either agent alone. Alternatively, an APF—active anti—progestin may be used in
combination with one or more conventional chemotherapeutic agents which are negative
for APF activity in the screening assay to e improved therapeutic efficacy as
compared to either agent alone (e. g., everolimus, trastuzumab, TMl—D, anti—HER2 drugs,
bevacizumab, or chemotherapy with agents such as paclitaxel, docetaxel, taxanes,
bicin, mal doxorubicin, pegylated liposomal doxorubicin, anthracyclines,
anthracenediones, carboplatin, cisplatin, S-FU, gemcitabine and cyclophosphamide). For
example, imus is an mTor inhibitor that is indicated in combination with an
ase inhibitor and may, in the future, be indicated in combination with an anti—
progestin.
In yet another aspect, detecting the presence of focal distribution of the
antibody to progesterone receptors in the nuclei may be used as an indication that the
tumor of a patient previously treated with an antitumor drug, which has become resistant
to that drug, is still sensitive to an APF-active anti—progestin such as onapristone. In one
aspect, the method can be adapted to determine whether chemoresistance of a tumor
resulting from previous chemotherapy can be reversed by ent with an APF—active
anti-progestin. Reversal of such esistance may be based on the different
mechanisms of action of the us chemotherapy and the APP—active anti—progestin.
Another aspect is directed to a system for fying a tumor susceptible
for treatment with an anti—progestin. The system comprises a tissue sample and at least
one antibody or antibody binding nt capable of detecting the progesterone receptor
wherein the antibody or dy binding fragment is used to determine the degree of
focal distribution of the progesterone receptor in the nuclei of cells from a tumor tissue
specimen and wherein the tumor is susceptible to ent with an anti-progestin if the
degree of focal distribution is greater than about 5%.
Example 1
Tumor specimens from patients with breast cancer (invasive ductal
carcinoma) and endometrial cancer were selected from the archives of Oscar Lambret
Cancer Center (Lille, France), anatomical pathological department. Patients had
previously provided consent for the use of their tissues for research purposes. Samples of
breast or endometrial tumor tissues which had been fixed in 4% formalin fixative and
embedded in paraffin were obtained.
lmmunohistochemistry (IHC) was performed on 3—4 um sections of the
archival breast or endometrial tumor tissues. The sections were deparaffinized, hydrated
and washed in g buffer (0.05 mol/L Tris/HCI, 0.15 mol/L NaCl, 0.05% Tween 20,
pH 7.6, Dako, Denmark, code S3006). Antigen retrieval was carried out with the Dako
Target Retrieval Solution (modified citrate buffer, pH 6.1, Dako, Denmark, code 81699)
in a water bath at 98°C for 20 min. Then, the sections were covered with the Dako
Peroxydase Block solution to block nous des at room ature (RT) for
min (Dako EnVision® +/HRP Mouse (DAB+) Kit, Dako, Denmark, code K4007),
washed and incubated with the y antibodies at the appropriate optimal dilutions at
RT for 60 min in a humidified chamber (Table 1). Following a 5—min. wash with
working buffer, the Dako Labelled Polymer (Dako EnVision® +/HRP Mouse (DAB+)
Kit, Dako, Denmark, code K4007) was used for the detection of the primary antibody
binding at RT for 30 min. gen (DAB) was then used with Substrate—Batch at
room temperature for 5—10 min and the sections were lightly counterstained with Gill’s
hematoxylin.
Negative controls were obtained by substitution of the primary antibodies
with isotype control mouse IgGl (Table 1) or with antibody t alone (wash buffer
negative control) in the immunohistochemical staining procedure.
Table 1. Antibodies used for immunohistoehemistry
Antibody Clone Dilutions Host / Isotype Supplier Code
PR,Aform 16 1:100 (3.6 Mouse lgGl PGR-312—LNovocastra
ug/ml) CB
1:200 (1.8
PR, B form SAN27 1:100 (04 Mouse lgGlK PGR—B—CE
Novocastra
ug/ml)
1:200 (0.2
rig/m1)
PR,A/B forms 1A6 1:40 (1.2 Mouse IgGl CE
, Novocastra
rig/m1)
1:80 (0.6
pig/ml)
PR, A/B forms 16SAN27 1:100 (2 ug/ml) Mouse IgGl Novocastra —L—
1:200 (l ug/ml) CE
Negative control DAK- 1:25 (4 ug/ml) Mouse IgGl Dako X0931
G01 1:100 (1 ug/ml)
1:200 (0.5
rig/m1)
Immunohistochemistry analysis was performed using a Zeiss Axioscope
microscope, equipped with an Imaging Model ROHS digital camera. lmmunoreactive
signals were classified as unequivocal brown labeling of tumor cell nuclei. The intensity
of labeling was defined as 0 for negative, + for weak, ++ for te and +++ for
strong.
Example 2
12 breast cancer samples were ed with 3 different antibodies and 4
methods in lHC. 6 samples could be processed for further immunohistofluorescence
(II-IF) analysis.
Immunohistofluorescence was med using a Zeiss fluorescent
cope equipped with a CCD camera and Smart Capture software, specific for
capture of cent images. IHF was performed on 3—4 um sections of the archival
breast tumor tissues. The sections were deparaffinized, hydrated and washed in working
buffer (0.05 mol/L Tris/HCl, 0.15 mol/L NaCl, 0.05% Tween 20, pH 7.6, Dako,
Denmark, code S3006). Antigen retrieval was carried out with the Dako Target val
bath at
Solution (modified citrate buffer, pH 6.1, Dako, Denmark, code 81699) in a water
98°C for 20 min. Then, the sections were incubated with the primary antibodies at the
appropriate optimal dilutions at RT for 60 min in a black humidified chamber (Table 2).
Following a 5-minute wash with working buffer, appropriate secondary antibody
conjugated to Alexa Fluor 488 was used for the detection of the primary antibody g
at RT for 30 min (Anti—mouse lgG (H+L), F(ab’)2, Cell Signaling, USA, code 44088,
dilution 121000 ; Anti—rabbit IgG (H+L), F(ab’)2, Cell Signaling, USA, code 44128,
dilution 1:1000). All slides were then washed and coverslipped using Vectashield®
HardSet Mounting Medium (Vector Labs, USA, code H—1400) and stored refrigerate
the dark until analysis, to preserve fluorescence. Negative controls were obtained by
substitution of the y dies with isotype control mouse lgGl or rabbit serum
(see lHC table) or with dy diluent alone (wash buffer ve control) in the
immunohistofluorescence staining procedure.
All tumor samples were PR Positive for the three different antibodies.
of 11 PR positive
However, the analysis of the nuclear pattern was lusive in 6 out
cases with the bispecific A and B antibody (1 case was PR negative with this antibody
only). Six cases were subjected to IHF analysis with all of the antibodies. In two cases,
the lHF procedure could not be performed with all antibodies because not enough tumor
tissue remained available. The four cases could be analyzed with the PR B antibody.
2012/058732
The IHF analysis with the other antibodies (PRA and PRA + B) was inconclusive in one
instance for terizing the nuclear pattern. The IHF PR r distribution and
binding patterns observed were concordant with IHC.
Thereafter, a larger sample was analyzed in lHC with the Anti—PR A
antibody, Anti—PR B antibody, or the mixture of both (called thereafter A+B).
75 breast cancers and 25 endometrial cancer samples were processed. For
each labeled tumor sample, ve focal distribution was defined as the percentage
d tumor cells in the entire tumor tissue, excluding necrotic areas.
The two basic patterns found are presented in Figure 1. These images
show the staining of tissue samples with anti—PR antibodies using (THC). Figure 1A
shows a brown, finely granular, and diffuse D pattern. Figure 1B shows a mottled,
clumped pattern representing a positive focal binding A pattern. Figure 2 shows the same
samples processed using IHF. Figure 2A shows a e D pattern similar to the IHC
result in Figure 2A. Figure 2B shows a similar mottled, clumped, focal g pattern as
in Figure 2B. The diffuse D pattern of Figures 1A and 2A are similar to the results
in gene-engineered cells that a fluorescent receptor when
ed express no
progesterone or no progesterone—agonist is present (Amett—Manfield et A1, 2004, 1C
Control, 1D, and 1E) and in normal human endometrial tissue and in endometrial cancer
(Arnett-Manfield et A1, 2004, 1A, 1B, 1C, 1D, 1E, 1F).
The active A pattern observed in formalin fixed, paraffin embedded tumor
tissue may differ from images obtained in fresh cells. This is expected because formalin—
fixation and paraffin embedding tissue will result in s to the cellular contents,
thereby ing in a different n of PR. Another difference relative to the ch
publications which utilized IHF, is related to the . In the research setting, a
confocal microscope (i.e. using two laser beams) provides high resolution and 3D
images; thin slices of tissue samples (e.g., 2 microns) are utilized. The IHC pattern
results from a chemical reaction that modifies the cellular content. In contrast for IHC, a
traditional wide-field microscope is used for reading the standard thicker tumor slices
resolution.
(e. g., 4 microns). The IHC technique described results in some loss of
The IHF technique is less chemically aggressive for tumor tissues, in that
it does not alter the copic cellular ecture. IHF requires specialized,
equipment, a pathologist experienced with the technique, and is much more time—
consuming. IHF cannot be easily coupled with other pathology analyses such as standard
ogy that requires formalin—fixed paraffin embedded tissues. Thus, in one aspect,
IHC may be used as a routine pathological laboratory procedure. In the developed IHC
technique used herein, 4 micrometer tissue sections (a commonly used thickness for
routine clinical analysis ) were used for all analysis.
Figures 3A and 3B are equivalent to Figures 1A and 1B with background
staining. The diffuse pattern observed in 5A, or in immunofluorescence, is darkened by
the counterstaining. Likewise, 5B demonstrates gross nuclear anomalies. r, the
even, e pattern of 5A is still characteristic with 5A with homogeneous nuclei, while
1B ated in dysformed nuclei in SE.
Thus, two basic patterns are found: a diffuse PR nuclear staining
indicating an absence of activated PRs, or and heterogeneous staining where aggregates,
called PR foci, can be recognized within the nucleus of the cells. PR foci are larger than
elements of a diffuse pattern that are substantially smaller (see Figures).
Example 3
Three categories or phenotypes have been fied for use with aspects
described herein and which are observed at higher magnification (800X). In st,
rd magnification (400X) is used in for conventional IHC PR status determination.
Categories (observed at high magnification)
D : Diffuse Staining, no PR Foci (e.g., Figure 1A)
] AD : Area associating A and D cells, or heterogeneous distribution of
PR foci with smaller sizes than A.
A Large Foci distributed in an heterogeneous manner (e.g., Figure
113)
This classification (D, AD, and A) was evaluated on 100 additional cases
(75 breast cancer and 25 endometrial cancer tissue samples). In some cases the samples
for PR-A but not for PR—
were positive for one PR e and not the other (e. g., positive
Breast Cancer Samples (61 cases are analyzed for standard PR expression,
12 cases were PR negative for all antibodies, 2 cases had missing data).
Table 2
Breast Cancer Tumor Cells Positive for Indicated Antibody
Number
In Percentages Mean Min Max
of Cases
* Each dy gives statistically similar data with the same average percent (31-
36%) of PR Positive cells and varying within the same range (5-95%).
* This is a computation that selects the t percentage of PR A or PR B, as it
of positive progesterone receptor cells
was apparent that with the antibodies used, the rate
was not the same for both antibodies in a same biopsy.
Table 3
Endometrial Cancer Cells Positive for Indicated Antibody
Anti—PR A Alone 21%
R B Alone
C. Focal Distribution
The section below describe the ncies of A, AD, D patterns and N
(negative, no PR staining). All cases were analyzed at high cation (800X). Two
demonstrate that the
breast evaluable. The data in table 4
cancer cases were not
classification varies with the antibody (PRA or PRB) used, and that there is more
variability among the antibodies for the AD pattern. This most likely reflects the inherent
deregulation of the two PR receptors (A and B) in cancer tissue. In certain aspects,
antibodies targeted at each of the PR isoforms may be used to provide additional
information for interpreting the results of the analysis. For e, a case may be “D”
with an anti—PR A antibody and “AD” with the second anti—PR B dy. Based on the
later classification of “AD”, a treatment with a anti-progestin would be potentially
appropriate. Similarly, a case may be “A” with an antibody t PR A and “AD” with
an dy against PR B, which could potentially require a different (higher) dose of the
rogestin because of the greater degree of malignant cell growth indicated by the
aberrant PR activity. Conventional IHC methods to determine PR cannot provide this
ation because they only indicate the ce or absence of hormone receptors
(i.e., ER and PR). In one aspect, the activated PR foci pattern based on analysis with 1 or
more separate antibodies would provide additional information for analyzing the
activated PR foci pattern.
Table 4 — PR Focal Distribution for Breast Cancer Cells
Number
AD Neg
In Number of cases Of cases'
71 h
In Percentages % ---u
Anti-PRAandB 600
Example 4
In the data set outlined in the tables below, a given tumor sample could be
APF ve for one antibody and APF positive for another and show a different
pattern for one antibody versus the other antibody. However, the results were generally
concordant between PR—A and PR-B antibodies. This concordance is shown on the
diagonal of the tabulations that follow below. The concordance n the two
sets of conditions is ghted in the shaded text box of the table. These results
rate that in certain aspects, more than one antibody would e additional
information to identify the APP nuclear distribution pattern.
Table 5 below compares the APF patterns with the PR A antibody in
relationship to the PR A+B antibody mixture in the breast cancer samples. A:
Aggregated Pattern with large foci, AD: mix of A Cells and D cells, or heterogeneous
medium—medium size foci. D: e pattern or absence of Activated PR. The columns
classify the cases according to the indicated binding pattern using only the PR-A
antibody while the rows classify the cases using PR—A + PR—B antibodies. The diagonal,
highlighted row shows the number of concordant cases, i.e., cases with the same binding
pattern using both methods. Other cells show discordant results, i.e., cases with different
binding patterns for each method.
Table 5: Comparison of the APF patterns with PR A versus PR A+B
Table 6: Breast cancer samples: Cross—tabulation of results obtained with an
anti—PR B antibody (PR B) vs the mixture of anti—PR A and R B (PR A+B).
Aggregated Pattern with large foci, AD: mix of A Cells and D cells, or heterogeneous
medium—medium size foci. D: diffuse pattern or absence of Activated PR. The columns
classify the cases according to the indicated binding pattern using only the PR-B dy
while the rows classify the cases using PR—A + PR—B antibodies. The diagonal,
highlighted row shows the number of concordant cases, i.e., cases with the same binding
pattern using both methods. Other cells show discordant results, i.e., cases with different
binding patterns for each method.
Table 6: Comparison of the APF ns with PR B versus PR A+B
Breast Cancer
Table 7: Breast cancer samples: Cross-tabulation of s obtained with an
anti—PR B antibody (PR B) vs an antibody anti—PR A (PR A). A: Aggregated Pattern
with large foci, AD: mix of A Cells and D cells, or heterogeneous —medium size
foci. D: diffuse pattern or absence of Activated PR. The columns classify the cases
according to the indicated g pattern using only the PR B antibody while the rows
classify the cases using PR A antibody. The diagonal, ghted row shows the number
of concordant cases, i.e., cases with the same binding pattern using both methods. Other
cells show discordant results, i.e., cases with different binding patterns for each method.
Table 7 ison of the APP patterns with PR A versus PR B
_-Breast Cancer
PR A n-
Endometrial Cancer
Similar patterns of PR nuclear distribution are observed in endometrial
cancer samples. lmportantly, normal fibroblasts were found in biopsy samples and were
noted to be PR positive. These normal fibroblasts had a D PR nuclear distribution
phenotype indicating that the PR in these normal cells were not activated, most likely
because the patients are post menopausal and thus are not producing logic levels of
progesterone. Therefore, the fibroblasts are not exposed to endogenous progesterone. In
contrast, cancer tissue was presenting activated form of PR (APF) even in absence of
physiological progesterone as indicated by the fibroblast pattern.
Table 8: Endometrial cancer samples: Cross—tabulation of results obtained
with an anti-PR A antibody (PR A) vs the mixture of Anti—PR A and an antibody Anti—PR
B (PR A+B). A: Aggregated Pattern with large foci, AD: mix of A Cells and D cells, or
heterogeneous medium—medium size foci. D: diffuse pattern or absence of Activated PR.
The s classify the cases according to the indicated binding n using only the
PR A dy while the rows classify the cases using PR A and PR B antibodies. The
diagonal, highlighted row shows the number of concordant cases, i.e., cases with the
same binding pattern using both methods. Other cells show discordant results, i.e., cases
with different binding ns for each method.
Table 8: Comparison of the APF patterns with PR A versus PR A+ B
Endometrial Cancer
T-otal
PR A+B
Table 9: Endometrial cancer samples: Cross—tabulation of results obtained
Anti—PR
with an anti-PR B antibody (PR B) vs the mixture of Anti—PR A and an antibody
D cells, or
B (PR A+B). A: Aggregated Pattern with large foci, AD: mix of A Cells and
of Activated PR.
heterogeneous medium—medium size foci. D: diffuse pattern or e
The columns classify the cases according to the indicated binding pattern using only
PR B antibody while the rows classify the cases using PR A and PR B antibodies.
diagonal, highlighted row shows the number of concordant cases, i.e., cases with the
same binding pattern using both methods. Other cells ShOW dant results, i.e., cases
with different binding patterns for each method.
Table 9: ison of the APF patterns with PR B versus PR A+B
Table 10: Endometrial cancer samples: Cross—tabulation of results obtained
with an anti—PR B antibody (PR B) vs an antibody Anti—PR A (PR A). A: Aggregated
Pattern with large foci, AD: mix of A Cells and D cells, or heterogeneous medium-
medium size foci. D: diffuse pattern or absence of Activated PR. The s classify
the cases according to the indicated binding pattern using only the PR B antibody while
the rows classify the cases using PR A antibody. The diagonal, highlighted row shows
the number of concordant cases, i.e., cases with the same binding pattern using both
methods. Other cells show discordant results, i.e., cases with different binding ns
for each method.
Table 10: Comparison of the APF patterns with PR B versus PR A
Endometrial Cancer
PRA n
In one aspect, the use of antibodies directed to PR—A and PR-B or bi-
c antibodies directed to PR-A and PR-B can be used together to identify the AD
pattern PR nuclear distribution pattern where use of a single dy (e.g., PR—A or PR-
B) may not identify the AD pattern in n cases.
In another aspect, the methods disclosed herein describe a PR nuclear
pattern in cancer biopsies shown using, for example, IHC, and confirmed using fresh
tissues and IHF. The e n is found in normal cells/tissues that are not exposed
to progestins under experimental and physiological ions. The diffuse nuclear
distribution pattern indicates that the PR of the tumor cells is not activated, and therefore
ent of the tumor with an antiprogestin is unlikely to be effective. In contrast, the
what is observed when experimental models
presence of the AD or A pattern is similar to
or normal cells are exposed to progestins. These patterns signal that PRS are activated
and transcriptionally activate in some cells and that treatment with antiprogestins is likely
to be effective in these cases.
Expression of these patterns (e.g., A and AD) is heterogeneous in tumors
and across different s, which is a characteristic of cancers. In st, the D
phenotype is homogeneous, a pattern consistent with a lack of PR biologic function. The
sion of PR and the phenotype we have described vary according to the expressed
and the
PR Isotype (A or B) and the antibody used (e.g., bispecific AB, A only, B only
mixture of A + B). This variability of the PR nuclear distribution pattern is not
cted in naturally occurring human cancers which are inherently heterogenous .
Example 5
The plot of shows the percent of breast cancer samples positive for
PR—A and PR—B for the three binding patterns, A, AD, and D. The results support the
conclusion that conventional
a positive progesterone receptor status determined by
herein.
s does not correlate with the ce of PRF distribution as described
Example 6
Table 11
Table 11 shows the percentage of “A” binding pattern cells for tissue
samples exhibiting both “A’ and “D” binding pattern cells. The column labeled “APR”
indicates the l pattern observed for the tissue sample while the “A%” column
Each
indicates the percentage of cells in the sample that exhibit the “A” binding pattern.
row shows the results for one case using both anti—PR—A and anti—PR—B dies or
each antibody alone.
Table 11 Percentage of Cells expressing the APF pattern with ent
antibodies
m % of Cells with APF APR % of Cells with APF APR % of Cells with APF
>>J>J> UUUU
Ill -—
-—-—
>> GOEH0101 HED
>DO 40%
>>DC]
AD 5%
gh the invention herein has been described with reference to
particular embodiments, it is to be understood that these embodiments are merely
illustrative of the principles and applications of the present invention. It will be apparent
to those skilled in the art that various modifications and variations can be made to the
method and systems bed herein without departing from the spirit and scope of the
invention. Thus, it is intended that the t invention include modifications and
variations that are within the scope of the appended claims and their equivalents.
Throughout the specification and , unless the context requires
otherwise, the word “comprise” or variations such as “comprises” or “comprising”,
will be understood to imply the inclusion of a stated integer or group of integers but
not the exclusion of any other integer or group of integers.
Claims (21)
1. An in vitro method of predicting the efficacy of one or more anti-progestin(s) on a tumor or suspected tumor comprising: a) fying progesterone receptor positive cells in a tissue sample suspected of being tumorigenic or ous from a patient; b) determining the degree of focal distribution of the progesterone receptor in nuclei of the progesterone positive cells from the tissue ; and c) determining whether the degree of focal distribution in the tissue sample is r than about 5% of the progesterone receptor positive cells.
2. The method of claim 1, further comprising determining the degree of focal distribution in nuclei in cells from the tissue sample by exposing the tissue to antiprogesterone receptor antibodies.
3. The method of claim 1, wherein the tumor or suspected tumor is selected from the group consisting of , brain, meningiomas, prostate, ovarian, endometrial, uterine leiomyoma, lung, and uterine tissue.
4. The method of claim 1, wherein the anti-progestin is selected from the group ting of onapristone, lonaprisan, istone, PF-02413873, telapristone, lilopristone, ORG2058, asoprisnil, and ulipristal.
5. The method of claim 1, wherein the degree of focal distribution is determined by fying the binding pattern of the progesterone receptor in the progesterone positive cells of the tissue.
6. The method of claim 5, wherein the binding pattern is selected from group consisting of diffuse (D), active (A), and active/diffuse (AD).
7. The method of claim 2, wherein at least two antibodies are used to determine the degree of focal distribution.
8. The method of claim 2, wherein the antibodies are selected from the group consisting of anti-PR-A antibody, anti-PR-B antibody, and a mixture of anti-PR-A and anti-PR-B antibodies, and bi-specific antibodies ed to PR-A and PR-B.
9. The method of claim 2, wherein the degree of focal distribution of the progesterone receptor is determined by a detection method selected from the group ting of immunohistochemistry, immunofluorescence, and Western blot.
10. Use of an anti-progestin composition in the manufacture of a medicament for treating a tumor susceptible to growth inhibition by one or more anti-progestin(s), wherein the susceptibility is determined by : a) exposing a tissue sample ted of being tumorigenic from a patient to an rogesterone or antibody; b) identifying progesterone receptor positive cells in the tissue sample; and c) determining the focal binding distribution of the progesterone receptor in nuclei of cells from the tissue such that if the focal binding distribution is greater than 5% of the progesterone receptor ve cells in the tissue sample with an A or AD g pattern, then the tumor is determined to be susceptible to growth inhibition by one or more anti-progestin(s).
11. The use according to claim 10, wherein the anti-progestin composition is in a dosage range of about 10 to about 200 mg per day.
12. The use of claim 10, wherein the tumor is selected from the group consisting of breast, brain, meningiomas, prostate, ovarian, endometrial, uterine leiomyoma, lung, and uterine tissues.
13. The use of claim 10, wherein the anti-progestin is selected from the group consisting of onapristone, isan, mifepristone, PF-02413873, telapristone, lilopristone, ORG2058, asoprisnil, and ulipristal.
14. The use of claim 10, wherein the degree of focal distribution is determined by identifying the binding pattern of progesterone receptor in the cells of the tissue.
15. The use of claim 10, wherein the antibody is ed from the group consisting of anti-PR-A antibody, anti-PR-B antibody, a cific antibody directed to PR-A and PR-B, and a mixture of anti-PR-A and anti-PR-B antibodies.
16. The use of onapristone in the manufacturing of a medicament for the treatment of a tumor comprising: identifying a patient exhibiting greater than about 5% focal distribution of the progesterone receptor in the cell nuclei of terone or positive cells in a tumor tissue biopsy.
17. Use of onapristone in the preparation of a medicament for the treatment of a tumor in a patient, wherein the tumor is susceptible to growth inhibition by onapristone, and wherein the t is identified as exhibiting greater than about 5% focal distribution of the progesterone receptor in the cell nuclei of progesterone receptor positive cells in a tumor tissue biopsy.
18. The use according to claim 16 or 17, wherein onapristone is in an amount of about 10 to about 200 mg per day.
19. The use of claim 16 or 17, further comprising the use of an anti-tumor compound ed from the group consisting of everolimus, trastuzumab, TM1-D, anti- HER2 drugs, bevacizumab, axel, docetaxel, taxanes, doxorubicin, liposomal doxorubicin, pegylated liposomal doxorubicin, anthracyclines, anthracenediones, carboplatin, cisplatin, 5-FU, gemcitabine and cyclophosphamide.
20. A method of ing a drug candidate for the ability to decrease focal distribution of the progesterone receptor in the nuclei of progesterone or positive cells in a tumor comprising:, ng a first tumor tissue specimen from the tumor to a drug candidate, exposing the first and at least a second tumor tissue specimen from the same tumor to anti-progesterone receptor antibodies, determining the degree of focal distribution of progesterone receptors in the nuclei of the progesterone receptor ve cells from the tumor tissue specimens, and determining if the focal distribution of the progesterone receptor in the tumor tissue specimen exposed to the drug candidate is decreased compared to tumor tissue specimens not d to the drug candidate, wherein if the drug candidate ses the focal distribution of the progesterone or in the progesterone receptor positive cells of the tissue specimen exposed to the drug candidate, the drug candidate is capable of decreasing focal distribution of the progesterone receptor in progesterone receptor ve cells of the tumor.
21. A system for classifying a tumor susceptible for treatment with an anti-progestin, comprising a tissue sample and at least one antibody or antibody binding fragment capable of detecting the progesterone receptor wherein the antibody or antibody binding fragment is used to determine the degree of focal distribution of the progesterone receptor in the progesterone receptor positive nuclei of cells from a tumor tissue specimen and wherein the tumor is susceptible to treatment with an anti-progestin if the degree of focal distribution in the cell nuclei of the progesterone ve cells is greater than about 5%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ717890A NZ717890B2 (en) | 2011-10-04 | 2012-10-04 | Methods and Systems for Identifying and Treating Anti-Progestin Sensitive Tumors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161542931P | 2011-10-04 | 2011-10-04 | |
US61/542,931 | 2011-10-04 | ||
PCT/US2012/058732 WO2013052652A1 (en) | 2011-10-04 | 2012-10-04 | Methods and systems for identifying and treating anti-progestin sensitive tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ623140A NZ623140A (en) | 2016-06-24 |
NZ623140B2 true NZ623140B2 (en) | 2016-09-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9046534B2 (en) | Methods and systems for identifying and treating anti-progestin sensitive tumors | |
US20170102388A1 (en) | Breast cancer diagnostics using rankl and opg | |
Arnould et al. | Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH) | |
Mote et al. | Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial | |
US20070031902A1 (en) | Predictive Methods For Cancer Chemotherapy | |
WO2015157343A1 (en) | Systems and methods for identifying progesterone receptor subtypes | |
EP3052129A2 (en) | Protein biomarker and uses thereof | |
Cowen et al. | Oestrogen receptor in breast cancer: Prognostic studies using a new immunohistochemical assay | |
EP2773962B1 (en) | Assay for predictive biomarkers of anti-estrogen efficacy | |
CN116137862A (en) | Use of tertiary lymphoid structures for prognosis of disease progression and treatment of cancer | |
NZ623140B2 (en) | Methods and systems for identifying and treating anti-progestin sensitive tumors | |
NZ717890B2 (en) | Methods and Systems for Identifying and Treating Anti-Progestin Sensitive Tumors | |
Kean-Hooi Teoh MBChB et al. | An analysis of predictive biomarkers in routine histopathological reporting of infiltrating ductal breast carcinoma in a tertiary hospital in Malaysia with a focus on limitations and directions for future development | |
Yang et al. | S30 Abstracts–General Sessions |